Industry Alliance Program

Industry Alliance Program
 
Delivering Opportunity

To Change Medicine Right now.

CIRM established the Industry Alliance Program (IAP) as a direct opportunity for the industry to partner with CIRM in accelerating the most promising stem cell, gene and regenerative medicine therapy programs to commercialization. Through the IAP, CIRM is a dedicated and proactive partner to industry and CIRM grantees.

 

CURRENT CIRM PARTNERS

Click on logos below to learn more
Vivo Capital
Panacea Venture Healthcare
BlueRock Therapeutics
Novo Nordisk
Frequency Therapeutics
Elevate Bio
Elevate Bio
 
Accelerate With Us
 
Industry Alliance Program Logo
Contact Us To
Learn More Today

Shyam Patel, Ph.D.,
Director, Business Development
Email: spatel@cirm.ca.gov

Quote mark

One of the greatest strengths of CIRM has been their focus on development of new stem cell therapies that can become real medicines. This support has allowed the stem cell gene therapy we developed to treat SCID babies to be advanced and licensed to Orchard Therapeutics who are working to make it available to patients across the country."

Dr. Donald Kohn, UCLA School of Medicine

 

CIRM grantees drew in over $8B
in biopharma industry partnerships.

LEARN MORE
  • Share
  • Print
  • PDF version

Latest Press Releases

CIRM-funded research programs are helping turn stem cells into cures. Browse our press release archive below to find out the latest advances. For even more breaking news, visit our blog, The Stem Cellar.

See all press releases